Photonic-Controlled Spirulina Delivers 1.64 µg Active B12 per 100 g in Icelandic Bioreactor Trial

The exploratory study, published in Discover Food, tested photonic management in closed photobioreactors to shift Arthrospira platensis metabolism away from pseudo-B12 analogs toward the cobalamin form humans can absorb. Controlled spectra and nutrient inputs yielded biomass also rich in antioxidants, while maintaining net-zero emissions through Iceland’s geothermal electricity. Scaling projections showed that reallocating 277,950 tonnes of annual output could meet the 2.4 µg daily RDA for 13.8 million children aged 1–3.

This addresses a gap left by conventional Spirulina, which prior analyses found supplied only inactive pseudo-B12, rendering it ineffective for replacing animal sources. The work aligns with global efforts to decarbonize micronutrient supply amid rising B12 deficiency affecting over one billion people, especially in low-meat diets. It also connects to parallel bioreactor advances in Denmark and Austria that optimize light for secondary metabolites.

Next steps require randomized human bioavailability trials and regulatory approval for food-grade claims. Larger pilots must verify consistent B12 titers at commercial volumes before the technology can displace livestock-derived B12 at meaningful scale.